SNDA submitted to FDA for venetoclax, acalabrutinib combo in CLL
The US Food and Drug Administration (FDA) received the supplemental New Drug Application for venetoclax (VENCLEXTA) and acalabrutinib (Calquence), an all-oral, fixed-duration regimen,
News
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Treatment post-relapse improves survival outcomes in patients with AML or MDS
A real-world study assessed outcomes in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) who relapsed following transplant and observed a
Multiple Myeloma
BELLINI trial does not show overall survival benefit for venetoclax versus placebo in myeloma
Final results of the phase 3 BELLINI trial showed no improvement in overall survival (OS) for patients with multiple myeloma (MM) when venetoclax
Lymphoma
Multiple Myeloma
News
FDA approves biosimilar tocilizumab‑anoh for treatment of CRS
The US Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of tocilizumab-anoh to include in the
SOHO 2025
Meeting News
Society Updates
Nothing beats SOHO in Houston in September
Register today at soho.click/2025. Become a member at soho.click/join.
Lymphoma
Indolent B-Cell Lymphomas
News
FDA grants priority review for liso-cel in relapsed or refractory MZL
The US Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for lisocabtagene maraleucel (liso-cel; Breyanzi) for adults with
Society Updates
Virtual SOHO Breakthroughs in Blood Cancers meeting launches November 20
The new meeting offers an accessible format that meets the needs of busy hematologic oncologists, bringing the best in patient care knowledge directly
News
EC approves obe-cel for relapsed or refractory B-ALL
The European Commission (EC) has granted marketing authorization to the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel; AUCATZYL) for adults ages 26
Lymphoma
Indolent B-Cell Lymphomas
EMA grants PRIME designation to Waldenstrom’s macroglobulinemia therapy BGB-16673
The European Medicines Agency (EMA) has granted (PRIority MEdicines) designation to the investigational Bruton’s tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of
Acute Myeloid Leukemia
Investigational CPX-531 plus venetoclax may be a salvage therapy option for relapsed or refractory AML
A study assessed CPX-531 plus venetoclax in patients with relapsed or refractory acute myeloid leukemia (AML) and found that the combination was particularly